ReviewOpen Access
Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies
Author Affiliations
University of Dhaka
Published InFrontiers in Pharmacology
Year2017
Citations111
Abstract
Thymoquinone (TQ), the main bioactive component of Nigella sative, has been found to exhibit anticancer effects in numerous preclinical studies. Due to its multitargeting nature, TQ interferes in a wide range of tumorigenic processes and counteract carcinogenesis, malignant growth, invasion, migration, and angiogenesis. Moreover, TQ can specifically sensitize tumor cells towards conventional cancer treatments (e.g. radiotherapy, chemotherapy, immunotherapy) and simultaneously minimize therapy-associated toxic effects in normal cells. In this review, we summarized the adjuvant potential of TQ as observed in various in vitro and in vivo animal models and discussed the pharmacological properties of TQ to rationalize its supplementary role in potentiating the efficacy of standard therapeutic modalities namely surgery, radiotherapy, chemotherapy, and immunotherapy. Altogether, we suggests further comprehensive evaluation…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.